ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2,1,Bile acids increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,1,Bile acid malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
5,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
5,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,1,Bile acids increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
6,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
7,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
7,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
8,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
